JMP Securities starts Astria Therapeutics stock with $26 target
Astria Therapeutics' focus on leveraging its half-life extension technology to create long-acting mAbs targeting derisked targets in established markets has positioned the company favorably in the ...
JMP Securities sets $19 target for Kalvista Pharmaceuticals stock
JMP Securities initiated coverage on Kalvista Pharmaceuticals Inc (NASDAQ: KALV), assigning a Market Outperform rating and setting a price target of $19.00. Currently trading at $8.77, the stock has ...
Astria Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target ...
KalVista initiated with an Outperform at JMP Securities
JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...
Chemistry World22h
Design of experiments: Smarter methods, better results
Even with its well-documented benefits, DoE is often underutilised, especially for solving specialised or constrained ...